CN Patent

CN107365275B — 高纯度的赛乐西帕

Assigned to Hangzhou Huadong Medicine Group Pharmaceutical Research Institute Co ltd · Expires 2020-07-03 · 6y expired

What this patent protects

本发明公开了一种高纯度的赛乐西帕。由赛乐西帕的关键中间体2‑(4‑((5，6‑二苯基吡嗪‑2‑基)异丙基氨基)丁氧基)乙酸在有机溶剂中与CDI、甲磺酰胺在有机碱的条件下反应制得。该反应操作简单，成本低，环境友好，收率＞95％，适于工业化生产，制得的赛乐西帕纯度≥99.9％，可很好地满足药物生产的要求。本发明制备得到的赛乐西帕纯度高，从而有利于后序得到更高品质的药品。

USPTO Abstract

本发明公开了一种高纯度的赛乐西帕。由赛乐西帕的关键中间体2‑(4‑((5，6‑二苯基吡嗪‑2‑基)异丙基氨基)丁氧基)乙酸在有机溶剂中与CDI、甲磺酰胺在有机碱的条件下反应制得。该反应操作简单，成本低，环境友好，收率＞95％，适于工业化生产，制得的赛乐西帕纯度≥99.9％，可很好地满足药物生产的要求。本发明制备得到的赛乐西帕纯度高，从而有利于后序得到更高品质的药品。

Drugs covered by this patent

Patent Metadata

Patent number
CN107365275B
Jurisdiction
CN
Classification
—
Expires
2020-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Huadong Medicine Group Pharmaceutical Research Institute Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.